mTOR Inhibitor Composition for Mutation-Linked Intractable Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Intractable epilepsy, particularly Focal Cortical Dysplasia (FCD), Hemimegalencephaly (HME), Hippocampal Sclerosis (HS), and Sturge-Weber Syndrome (SWS), are difficult to treat with existing antiepileptic drugs and require surgical intervention due to a lack of understanding of their molecular genetic etiology, especially as somatic mutations in the PI3K-AKT-mTOR pathway remain undetected by conventional sequencing methods.
Innovation Solution
Identification of specific somatic mutations in the PI3K-AKT-mTOR pathway through deep sequencing, development of a biomarker panel, and use of mTOR inhibitors like rapamycin and everolimus to suppress hyperactivation of the pathway, reducing seizures and abnormal neuronal morphology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional sequencing methods are used to detect somatic mutations, then the sequencing process is simple and fast, but the detection precision is insufficient to identify low-frequency somatic mutations in FCD
Solution Approach 1:
The patent divides the detection process into multiple stages: initial capture of target DNA regions using hybridization probes, followed by multiple rounds of PCR amplification and sequencing. This segmentation allows deep sequencing of specific regions to detect low-frequency somatic mutations that conventional methods miss, while managing complexity through structured multi-step processing
Solution Approach 2:
The patent performs preliminary enrichment of target DNA regions containing potential somatic mutations before sequencing. By using hybridization capture and selective amplification beforehand, the method concentrates rare mutant alleles, enabling their detection with sufficient precision without requiring equally complex sequencing technology
2Reliability
If surgical resection is performed to treat FCD, then seizure freedom is achieved in approximately 60% of patients, but a significant portion of patients continues to have seizures
Solution Approach 1:
The patent uses mTOR inhibitors to activate the body's own regulatory mechanisms against abnormal neuronal growth. By inhibiting the hyperactive mTOR pathway that drives FCD pathology, the treatment enables endogenous control of seizure activity without requiring additional surgical intervention, thereby improving seizure control reliability while avoiding surgical risks
3Productivity
If mTOR inhibitors are used to treat intractable epilepsy, then seizure frequency decreases and abnormal neuronal morphology is reduced, but the treatment targets underlying genetic mutations that were previously undetected
Solution Approach 1:
The patent establishes a feedback loop where deep sequencing first identifies somatic mutations in the PI3K-AKT-mTOR pathway, then guides the selection of mTOR inhibitor treatment. This information feedback from molecular diagnosis to targeted therapy ensures therapeutic effectiveness by matching treatment to the specific genetic etiology, while the treatment success further validates the molecular diagnosis
Data Source
AI summary
Provided is a use of the prophylaxis, amelioration or therapy of intractable epilepsy, for example, Focal Cortical Dysplasia (FCD).